Biohaven Ltd. (NYSE:BHVN) stock plummeted on Wednesday, reaching its 52-week low, according to data from Benzinga Pro.BHVN is testing key support levels. View the charts hereThe U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Biohaven's New Drug Application (NDA) seeking approval of Vyglxia (troriluzole) for spinocerebellar ataxia (SCA).FDA cited issues that can be inherent to real-world evidence and external control studies, including potential bias, design flaws, lack of ...